期刊
JACC-BASIC TO TRANSLATIONAL SCIENCE
卷 6, 期 9-10, 页码 772-795出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jacbts.2021.06.002
关键词
atrial shunt devices; electrostimulation; heart failure devices; heart failure with preserved ejection fraction; HFpEF; left ventricular expanders; mechanical circulatory support; neuromodulation
资金
- Enterprise Ireland through their Commercialization Fund [CF-2019-1136-P]
- European Regional Development Fund under Ireland's European Structural and Investment Funds Programme
Heart failure with preserved ejection fraction (HFpEF), characterized by rapidly increasing prevalence, elevated mortality and rehospitalization rates, has led to the development of device-based solutions to target its associated symptoms. Although promising results have been shown in studies, no device-based therapy has been approved for HFpEF treatment so far.
Characterized by a rapidly increasing prevalence, elevated mortality and rehospitalization rates, and inadequacy of pharmaceutical therapies, heart failure with preserved ejection fraction (HFpEF) has motivated the widespread development of device-based solutions. HFpEF is a multifactorial disease of various etiologies and phenotypes, distinguished by diminished ventricular compliance, diastolic dysfunction, and symptoms of heart failure despite a normal ejection performance; these symptoms include pulmonary hypertension, limited cardiac reserve, autonomic imbalance, and exercise intolerance. Several types of atrial shunts, left ventricular expanders, stimulation-based therapies, and mechanical circulatory support devices are currently under development aiming to target one or more of these symptoms by addressing the associated mechanical or hemodynamic hallmarks. Although the majority of these solutions have shown promising results in clinical or preclinical studies, no device-based therapy has yet been approved for the treatment of patients with HFpEF. The purpose of this review is to discuss the rationale behind each of these devices and the findings from the initial testing phases, as well as the limitations and challenges associated with their clinical translation. (C) 2021 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据